Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03847428 · ClinicalTrials.gov registry record · Phase 3

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

A Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
908
Enrollment target
20
Study locations

NCT03847428 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 908 participants, above the 251-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (262% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03847428, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
908 participants
Enrollment target
20
Study locations

Study Summary

A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.

Conditions Studied

Hepatocellular Carcinoma

Interventions

  • DRUG Bevacizumab
  • OTHER Placebo
  • DRUG Durvalumab

Study Locations (20)

California

  • Research Site - Costa Mesa
  • Research Site - La Jolla
  • Research Site - Long Beach
  • Research Site - Orange
  • Research Site - Sacramento

Alabama

  • Research Site - Birmingham
  • Research Site - Mobile

Florida

  • Research Site - Miami
  • Research Site - Tampa

Michigan

  • Research Site - Detroit
  • Research Site - Grand Rapids

Arizona

  • Research Site - Phoenix

District of Columbia

  • Research Site - Washington D.C.

Hawaii

  • Research Site - Honolulu

Illinois

  • Research Site - Chicago

Trial Details

FieldValue
Enrollment Target 908 participants
Start Date 2019-04-29
Est. Completion 2027-05-31
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03847428

The ClinicalTrials.gov registry entry for NCT03847428 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 908 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 251-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (262% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT03847428 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT03847428 about?

NCT03847428 is a clinical study titled "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment". A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.

What is the current status of trial NCT03847428?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 908 participants. The study started on 2019-04-29. Estimated completion is 2027-05-31.

What conditions does trial NCT03847428 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT03847428?

The interventions under investigation include: Bevacizumab (DRUG), Placebo (OTHER), Durvalumab (DRUG).

Who is sponsoring clinical trial NCT03847428?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03847428 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.